Amarillo Biosciences, Inc. Receives Approval of Patent Claims – Treatment of Thrombocytopenia Using Orally Administered Interferon
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR), today announced that eight claims of its latest patent application, which apply the use of low-dose oral interferon to the reversal of Thrombocytopenia, have been allowed by the U.S. Patent & Trademark Office. The…